During the past decade, Unità Ematologia Ospedale Civile di Piacenza conducted 0 clinical trials. In the 10-year time frame, 0 clinical trials started and 0 clinical trials were completed, i.e. on average, 0% percent of trials that started reached the finish line to date. In the past 5 years, 0 clinical trials started and 0 clinical trials were completed. i.e. 0% of trials that started reached the finish line.

According to Clinical.Site data, the most researched conditions in "Unità Ematologia Ospedale Civile di Piacenza" are "Mantle Cell Lymphoma" (1 trials) and "Relapsed Follicular Lymphoma" (1 trials). Many other conditions were trialed in "Unità Ematologia Ospedale Civile di Piacenza" in a lesser frequency.

Most popular intervention types in "Unità Ematologia Ospedale Civile di Piacenza" are "Drug" (2 trials) and "Other" (1 trials). Other intervention types were less common.

The name of intervention was led by "BEAM" (1 trials), "Bendamustine, Lenalidomide, Rituximab" (1 trials) and "ZEVALIN" (1 trials). Other intervention names were less common.

The vast majority of trials in "Unità Ematologia Ospedale Civile di Piacenza" are 2 trials for "All" genders.

Currently, there are NaN active trials in "Unità Ematologia Ospedale Civile di Piacenza". undefined are not yet recruiting, undefined are recruiting, 1 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 1 completed trials in Unità Ematologia Ospedale Civile di Piacenza, undefined suspended trials, and undefined terminated clinical trials to date.

Out of the total trials that were conducted in Unità Ematologia Ospedale Civile di Piacenza, 0 "Phase 1" clinical trials were conducted, 1 "Phase 2" clinical trials and 1 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 0 trials that are defined as “Not Applicable".